vs
Side-by-side financial comparison of COMSCORE, INC. (SCOR) and Vericel Corp (VCEL). Click either name above to swap in a different company.
COMSCORE, INC. is the larger business by last-quarter revenue ($93.5M vs $92.9M, roughly 1.0× Vericel Corp). Vericel Corp runs the higher net margin — 25.0% vs 3.2%, a 21.8% gap on every dollar of revenue. On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs -1.5%). Vericel Corp produced more free cash flow last quarter ($12.8M vs $2.9M). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 3.8%).
Comscore, Inc. is an American-based global media measurement and analytics company providing marketing data and analytics to enterprises, advertising agencies, brand marketers, and publishers.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
SCOR vs VCEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $93.5M | $92.9M |
| Net Profit | $3.0M | $23.2M |
| Gross Margin | 41.0% | 78.7% |
| Operating Margin | 7.0% | 24.1% |
| Net Margin | 3.2% | 25.0% |
| Revenue YoY | -1.5% | 23.3% |
| Net Profit YoY | -3.7% | 17.3% |
| EPS (diluted) | $9.50 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $93.5M | $92.9M | ||
| Q3 25 | $88.9M | $67.5M | ||
| Q2 25 | $89.4M | $63.2M | ||
| Q1 25 | $85.7M | $52.6M | ||
| Q4 24 | $94.9M | $75.4M | ||
| Q3 24 | $88.5M | $57.9M | ||
| Q2 24 | $85.8M | $52.7M | ||
| Q1 24 | $86.8M | $51.3M |
| Q4 25 | $3.0M | $23.2M | ||
| Q3 25 | $453.0K | $5.1M | ||
| Q2 25 | $-9.5M | $-553.0K | ||
| Q1 25 | $-4.0M | $-11.2M | ||
| Q4 24 | $3.1M | $19.8M | ||
| Q3 24 | $-60.6M | $-901.0K | ||
| Q2 24 | $-1.7M | $-4.7M | ||
| Q1 24 | $-1.1M | $-3.9M |
| Q4 25 | 41.0% | 78.7% | ||
| Q3 25 | 40.6% | 73.5% | ||
| Q2 25 | 40.6% | 73.7% | ||
| Q1 25 | 39.6% | 69.0% | ||
| Q4 24 | 42.4% | 77.6% | ||
| Q3 24 | 41.2% | 71.9% | ||
| Q2 24 | 39.5% | 69.5% | ||
| Q1 24 | 42.3% | 68.9% |
| Q4 25 | 7.0% | 24.1% | ||
| Q3 25 | 1.9% | 5.1% | ||
| Q2 25 | -1.9% | -3.2% | ||
| Q1 25 | -2.4% | -24.3% | ||
| Q4 24 | 4.1% | 24.5% | ||
| Q3 24 | -67.4% | -4.3% | ||
| Q2 24 | -2.2% | -11.5% | ||
| Q1 24 | -2.2% | -10.7% |
| Q4 25 | 3.2% | 25.0% | ||
| Q3 25 | 0.5% | 7.5% | ||
| Q2 25 | -10.6% | -0.9% | ||
| Q1 25 | -4.7% | -21.4% | ||
| Q4 24 | 3.3% | 26.3% | ||
| Q3 24 | -68.5% | -1.6% | ||
| Q2 24 | -2.0% | -8.9% | ||
| Q1 24 | -1.2% | -7.5% |
| Q4 25 | $9.50 | $0.46 | ||
| Q3 25 | $-0.86 | $0.10 | ||
| Q2 25 | $-2.73 | $-0.01 | ||
| Q1 25 | $-1.66 | $-0.23 | ||
| Q4 24 | $-0.47 | $0.40 | ||
| Q3 24 | $-12.79 | $-0.02 | ||
| Q2 24 | $-1.19 | $-0.10 | ||
| Q1 24 | $-1.08 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $23.6M | $137.5M |
| Total DebtLower is stronger | $41.5M | — |
| Stockholders' EquityBook value | $111.4M | $354.6M |
| Total Assets | $407.7M | $488.0M |
| Debt / EquityLower = less leverage | 0.37× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $23.6M | $137.5M | ||
| Q3 25 | $26.7M | $135.4M | ||
| Q2 25 | $26.0M | $116.9M | ||
| Q1 25 | $31.0M | $112.9M | ||
| Q4 24 | $29.9M | $116.2M | ||
| Q3 24 | $20.0M | $101.7M | ||
| Q2 24 | $14.7M | $102.5M | ||
| Q1 24 | $18.7M | $110.6M |
| Q4 25 | $41.5M | — | ||
| Q3 25 | $41.4M | — | ||
| Q2 25 | $41.3M | — | ||
| Q1 25 | $41.3M | — | ||
| Q4 24 | $41.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $111.4M | $354.6M | ||
| Q3 25 | $-26.3M | $321.9M | ||
| Q2 25 | $-21.7M | $306.8M | ||
| Q1 25 | $-13.5M | $295.5M | ||
| Q4 24 | $-8.3M | $292.0M | ||
| Q3 24 | $-2.7M | $257.5M | ||
| Q2 24 | $45.8M | $243.0M | ||
| Q1 24 | $51.4M | $233.9M |
| Q4 25 | $407.7M | $488.0M | ||
| Q3 25 | $406.9M | $453.3M | ||
| Q2 25 | $415.9M | $435.6M | ||
| Q1 25 | $421.5M | $424.6M | ||
| Q4 24 | $430.2M | $432.7M | ||
| Q3 24 | $412.5M | $390.4M | ||
| Q2 24 | $474.1M | $376.8M | ||
| Q1 24 | $477.7M | $356.7M |
| Q4 25 | 0.37× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.2M | $15.0M |
| Free Cash FlowOCF − Capex | $2.9M | $12.8M |
| FCF MarginFCF / Revenue | 3.1% | 13.8% |
| Capex IntensityCapex / Revenue | 0.3% | 2.4% |
| Cash ConversionOCF / Net Profit | 1.07× | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | $21.8M | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.2M | $15.0M | ||
| Q3 25 | $9.5M | $22.1M | ||
| Q2 25 | $932.0K | $8.2M | ||
| Q1 25 | $9.1M | $6.6M | ||
| Q4 24 | $-10.0M | $22.2M | ||
| Q3 24 | $12.5M | $10.2M | ||
| Q2 24 | $8.7M | $18.5M | ||
| Q1 24 | $6.9M | $7.2M |
| Q4 25 | $2.9M | $12.8M | ||
| Q3 25 | $9.4M | $19.5M | ||
| Q2 25 | $787.0K | $81.0K | ||
| Q1 25 | $8.7M | $-7.6M | ||
| Q4 24 | $-10.3M | $8.5M | ||
| Q3 24 | $12.4M | $-9.2M | ||
| Q2 24 | $8.5M | $1.8M | ||
| Q1 24 | $6.6M | $-6.8M |
| Q4 25 | 3.1% | 13.8% | ||
| Q3 25 | 10.5% | 28.8% | ||
| Q2 25 | 0.9% | 0.1% | ||
| Q1 25 | 10.1% | -14.5% | ||
| Q4 24 | -10.8% | 11.2% | ||
| Q3 24 | 14.0% | -15.9% | ||
| Q2 24 | 10.0% | 3.4% | ||
| Q1 24 | 7.6% | -13.3% |
| Q4 25 | 0.3% | 2.4% | ||
| Q3 25 | 0.1% | 3.9% | ||
| Q2 25 | 0.2% | 12.9% | ||
| Q1 25 | 0.4% | 27.0% | ||
| Q4 24 | 0.2% | 18.3% | ||
| Q3 24 | 0.1% | 33.5% | ||
| Q2 24 | 0.2% | 31.8% | ||
| Q1 24 | 0.3% | 27.3% |
| Q4 25 | 1.07× | 0.65× | ||
| Q3 25 | 20.96× | 4.35× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -3.19× | 1.12× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SCOR
| Transferred Over Time | $77.1M | 83% |
| Research Insight Solutions | $14.6M | 16% |
| Related Party | $2.5M | 3% |
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
